Refractory Angina Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | CellPraxis Bioengenharia, Angionetics, XyloCor Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Refractory Angina pipeline constitutes 3+ key companies continuously working towards developing 3+ Refractory Angina treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Refractory Angina Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Refractory Angina Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/refractory-angina-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Refractory Angina Market.

Some of the key takeaways from the Refractory Angina Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Refractory Angina treatment therapies with a considerable amount of success over the years.

*
Refractory Angina companies working in the treatment market are CellPraxis Bioengenharia Ltda., Angionetics Inc., XyloCor Therapeutics, Inc., Centocor, Inc., Lisata Therapeutics, Inc., and others, are developing therapies for the Refractory Angina treatment

*
Emerging Refractory Angina therapies in the different phases of clinical trials are- Minithoracotomy, Ad5FGF-4, AdVEGFXC1, Abciximab, Auto-CD34+ cells, CLBS14 (low-dose), and others are expected to have a significant impact on the Refractory Angina market in the coming years.

*
In April 2024, Shockwave Medical, Inc. (NASDAQ: SWAV), a leader in developing innovative technologies for cardiovascular disease treatment, announced that investigators have presented six-month data from the complete population of the REDUCER-I study, along with interim long-term follow-up results extending to three years. These findings validate the positive, real-world outcomes of Shockwave Reducer, a cutting-edge technology designed for the treatment of refractory angina.

*
In July 2023, XyloCor Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative gene therapies for cardiovascular disease, has announced positive 12-month data from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT). This trial is designed to evaluate the safety and preliminary efficacy of their lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in patients with refractory angina. At the 12-month extension mark, XC001 showed sustained improvements across various efficacy measures, including increased total exercise duration and reductions in both ischemic burden and symptoms. Earlier this year, XyloCor reported favorable results at six months from the primary study period of the Phase 2 EXACT trial. The new 12-month results emphasize the significant and clinically meaningful benefits of XC001, suggesting its potential as a novel therapeutic option for the unmet medical needs of patients with refractory angina.

Refractory Angina Overview

Refractory angina is a chronic condition characterized by persistent chest pain due to coronary artery disease (CAD) that is not adequately managed by conventional medical treatments, angioplasty, or coronary artery bypass surgery. Patients with refractory angina experience frequent and debilitating chest pain despite optimal medical therapy and revascularization attempts.

Get a Free Sample PDF Report to know more about Refractory Angina Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight [https://www.delveinsight.com/report-store/refractory-angina-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Refractory Angina Drugs Under Different Phases of Clinical Development Include:

*
Minithoracotomy: CellPraxis Bioengenharia Ltda.

*
Ad5FGF-4: Angionetics Inc.

*
AdVEGFXC1: XyloCor Therapeutics, Inc.

*
Abciximab: Centocor, Inc.

*
Auto-CD34+ cells: Lisata Therapeutics, Inc.

*
CLBS14 (low-dose): Lisata Therapeutics, Inc

Refractory Angina Route of Administration

Refractory Angina pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Refractory Angina Molecule Type

Refractory Angina Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Refractory Angina Pipeline Therapeutics Assessment

*
Refractory Angina Assessment by Product Type

*
Refractory Angina By Stage and Product Type

*
Refractory Angina Assessment by Route of Administration

*
Refractory Angina By Stage and Route of Administration

*
Refractory Angina Assessment by Molecule Type

*
Refractory Angina by Stage and Molecule Type

DelveInsight's Refractory Angina Report covers around 3+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Refractory Angina product details are provided in the report. Download the Refractory Angina pipeline report to learn more about the emerging Refractory Angina therapies [https://www.delveinsight.com/sample-request/refractory-angina-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Refractory Angina Therapeutics Market include:

Key companies developing therapies for Refractory Angina are - Angionetics Inc., Xylocor Therapeutics, Imbria Pharmaceuticals, Caladrius Biosciences, Inc., and others.

Refractory Angina Pipeline Analysis:

The Refractory Angina pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Angina with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Angina Treatment.

*
Refractory Angina key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Refractory Angina Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Angina market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Refractory Angina drugs and therapies [https://www.delveinsight.com/sample-request/refractory-angina-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of Refractory Angina Pipeline Drug Insight

*
Coverage: Global

*
Key Refractory Angina Companies: CellPraxis Bioengenharia Ltda., Angionetics Inc., XyloCor Therapeutics, Inc., Centocor, Inc., Lisata Therapeutics, Inc., and others

*
Key Refractory Angina Therapies: Minithoracotomy, Ad5FGF-4, AdVEGFXC1, Abciximab, Auto-CD34+ cells, CLBS14 (low-dose), and others

*
Refractory Angina Therapeutic Assessment: Refractory Angina current marketed and Refractory Angina emerging therapies

*
Refractory Angina Market Dynamics: Refractory Angina market drivers and Refractory Angina market barriers

Request for Sample PDF Report for Refractory Angina Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/refractory-angina-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Refractory Angina Report Introduction

2. Refractory Angina Executive Summary

3. Refractory Angina Overview

4. Refractory Angina- Analytical Perspective In-depth Commercial Assessment

5. Refractory Angina Pipeline Therapeutics

6. Refractory Angina Late Stage Products (Phase II/III)

7. Refractory Angina Mid Stage Products (Phase II)

8. Refractory Angina Early Stage Products (Phase I)

9. Refractory Angina Preclinical Stage Products

10. Refractory Angina Therapeutics Assessment

11. Refractory Angina Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Refractory Angina Key Companies

14. Refractory Angina Key Products

15. Refractory Angina Unmet Needs

16 . Refractory Angina Market Drivers and Barriers

17. Refractory Angina Future Perspectives and Conclusion

18. Refractory Angina Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=refractory-angina-pipeline-and-clinical-trials-assessment-2024-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-cellpraxis-bioengenharia-angionetics-xylocor-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.